Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
DEERFIELD, IL -- (Marketwired) -- 03/27/14 --   Horizon Pharma, Inc.
(NASDAQ: HZNP) today announced that on March 27, 2014 the
Compensation Committee of its Board of Directors approved the grant
of inducement stock options to purchase an aggregate of 96,750 shares
of common stock to 26 new employees. 
Each stock option has an exercise price per share equal to $15.08,
the fair market value on the grant date, and vests over four years,
with 25% of the shares vesting on the one-year anniversary of the
applicable vesting commencement date and 1/48 of the shares vesting
monthly thereafter, subject to the new employee's continued service
relationship with the Company. Each stock option also has a ten year
term and is subject to the terms and conditions of the Company's 2011
Equity Incentive Plan and the stock option agreement pursuant to
which the option was granted. 
The stock options were granted as inducements material to the new
employees entering into employment with Horizon Pharma in accordance
with NASDAQ Listing Rule 5635(c)(4). 
About Horizon Pharma
 Horizon Pharma, Inc. is a commercial stage,
specialty pharmaceutical company that markets DUEXIS(R), VIMOVO(R)
and RAYOS(R)/LODOTRA(R), which target unmet therapeutic needs in
arthritis, pain and inflammatory diseases. The Company's strategy is
to develop, acquire or in-license additional innovative medicines
where it can execute a targeted commercial approach among specific
target physicians such as primary care physicians, orthopedic
surgeons, and rheumatologists, while taking advantage of its
commercial strengths and the infrastructure the Company has put in
place. For more information, please visit www.horizonpharma.com. 
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.